Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | CES1 | P23141 | 1/20 | 0.38 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.37 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.37 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.37 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.37 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.37 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.37 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.37 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.37 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2208720 | 0.82 | POLB (0.42) | POLBLMNAKCNN4CYP2C19HIF1A | |
| SCHEMBL4943858 | 0.81 | KMT2A (0.50) | MAPTKMT2APOLBLMNACYP2C19 | |
| SCHEMBL10357848 | 0.78 | POLB (0.41) | POLBLMNACYP2C19HIF1AALDH1A1 | |
| SCHEMBL9255616 | 0.78 | PPARG (0.43) | MAPTKMT2APOLBLMNACYP2C19 | |
| SCHEMBL11376258 | 0.74 | MAPT (0.50) | MAPTKMT2APOLBLMNAKCNN4 | |
| SCHEMBL7167664 | 0.73 | POLB (0.41) | POLBLMNACYP2C19CES1HDAC1 | |
| SCHEMBL1195864 | 0.73 | CES1 (0.57) | MAPTKMT2ALMNACYP2C19HIF1A | |
| SCHEMBL4447460 | 0.72 | KMT2A (0.57) | MAPTKMT2APOLBLMNAKCNN4 | |
| SCHEMBL28602564 | 0.72 | MAPT (0.57) | MAPTKMT2AKCNN4CYP2C19HIF1A | |
| SCHEMBL270134 | 0.72 | MAPT (0.57) | MAPTKMT2AKCNN4CYP2C19HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4682141-A1 | TRICYCLIC COMPOUND | ONO Pharmaceutical Co., Ltd. (JP) | 2026-01-21 | — | — | EP | disclosed |
| WO-2024190780-A1 | PROPHYLACTIC AND/OR THERAPEUTIC AGENT FOR KIDNEY DISEASES CONTAINING TRICYCLIC COMPOUND | 小野薬品工業株式会社 | 2024-09-19 | — | — | WO | disclosed |
| WO-2024190777-A1 | TRICYCLIC COMPOUND | 小野薬品工業株式会社 | 2024-09-19 | — | — | WO | disclosed |
| US-20040254230-A1 | Method for treating ocular hypertension | MERCK FROSST CANADA LTD. (CA) | 2004-12-16 | — | — | US | disclosed |
| EP-1461026-A2 | METHOD FOR TREATING OCULAR HYPERTENSION | Merck & Co., Inc. (US) | 2004-09-29 | — | — | EP | disclosed |
| WO-2003047513-A2 | METHOD FOR TREATING OCULAR HYPERTENSION | MERCK & CO., INC. (US) | 2003-06-12 | — | — | WO | disclosed |
| EP-0389162-B1 | 2,5,6,7-Tetranor-4,8-inter-m-phenylene PGI2 derivatives | TORAY INDUSTRIES (JP) | 1993-12-08 | — | — | EP | disclosed |
| US-5086071-A | Improved chemical stability and ppotent in vivo | TORAY INDUSTRIES, INC. (JP) | 1992-02-04 | — | — | US | disclosed |
| EP-0389162-A1 | 2,5,6,7-Tetranor-4,8-inter-m-phenylene PGI2 derivatives | TORAY INDUSTRIES, INC. (JP) | 1990-09-26 | — | — | EP | disclosed |
| US-4775692-A | ANTILIPEMIC, ANTICOAGULANT, HYPOTENSIVE, ANTISECRETORY AND ANTIULCER AGENT | TORAY INDUSTRIES, INC. (JP) | 1988-10-04 | — | — | US | disclosed |
| EP-0232776-A2 | 2,5,6,7-tetranor-4,8-inter-m-phenylene PGI2 derivatives | TORAY INDUSTRIES, INC. (JP) | 1987-08-19 | — | — | EP | disclosed |
| EP-0079694-B1 | 7-OXABICYCLOPHEPTANE AND 7-OXABICYCLOHEPTENE COMPOUNDS | E.R. Squibb & Sons, Inc. (US) | 1987-05-13 | — | — | EP | disclosed |
| US-4614825-A | 7-oxabicycloheptane and 7-oxabicycloheptene compounds | E. R. SQUIBB & SONS, INC. (US) | 1986-09-30 | — | — | US | disclosed |
| US-4556675-A | 7-Oxabicycloheptane and 7-oxabicycloheptene compounds | E. R. SQUIBB & SONS, INC. (US) | 1985-12-03 | — | — | US | disclosed |
| US-4537981-A | 7-Oxabicycloheptane and 7-oxabicycloheptene compounds | E. R. SQUIBB & SONS, INC. (US) | 1985-08-27 | — | — | US | disclosed |
| US-4537904-A | Compositions of 7-oxabicycloheptane and 7-oxabicycloheptene compounds and a method for their use in inhibiting bronchoconstriction | E. R. SQUIBB & SONS, INC. (US) | 1985-08-27 | — | — | US | disclosed |
| US-4463015-A | Aryl substituted 7-oxabicycloheptane compounds, useful in inhibiting platelet aggregation | E. R. SQUIBB & SONS, INC. (US) | 1984-07-31 | — | — | US | disclosed |
| EP-0079694-A1 | 7-Oxabicyclopheptane and 7-oxabicycloheptene compounds | E.R. Squibb & Sons, Inc. (US) | 1983-05-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040254230-A1 | Method for treating ocular hypertension | PTGIR, PTGER4, PTGER1 | MAPT 4146/4885KMT2A 3736/4885POLB 4406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.